After-market Movers For April 28 (TWTR, GPRO, XPO, WYNN, SSYS, BWLD, AKAM, X)


GoPro, Inc. (GPRO) gained 10 percent to $51.90. The company's first quarter earnings improved from the year-ago quarter and its adjusted earnings per share topped Street view. Revenue increased 54 percent and also came above the consensus estimate. The company also announced an agreement to acquire Kolor, a leader in virtual reality and spherical media solutions.

XPO Logistics, Inc. (XPO) rose 11 percent to $47.10 based on the news that it has agreed to acquire contract logistics provider Norbert Dentressangle SA in transaction valued at approximately EUR 3.24 billion, including EUR 1.08 billion of net debt. XPO expects this acquisition to more than triple its EBITDA run rate and increase its revenue to $8.5 billion, nearly achieving its 2017 targets two years ahead of plan.


Twitter, Inc. (TWTR) fell 2 percent to $41.50 after closing the day's regular session down 18 percent at $42.27, after its weak earnings report that was leaked an hour earlier than expected. The company's first quarter net loss widened from the year-ago quarter, while its adjusted earnings per share topped Street view. Revenue improved 74 percent year-over-year, but missed both its prior forecast and analysts' estimate, affected by a lower-than-expected contribution from its newer direct response products. The company also forecast second quarter and 2015 revenues below Street view.

Wynn Resorts Ltd. (WYNN) fell 10 percent to $116.82. The company slipped to a loss in its first quarter and its adjusted per share missed Street view. Net revenues declined and also missed the consensus estimate. Wynn Resorts also announced a reduction in its quarterly cash dividend.

Stratasys Ltd. (SSYS) plunged 16 percent to $42.84 as it forecast first quarter non-GAAP earnings and revenue sharply below Street view. The company also expects to report a loss for its first quarter on a GAAP basis. The company also slashed its full-year 2015 forecast.

Internap Corp. (INAP) declined 16 percent to $8.75 as its first quarter results were below analysts' expectations. The company also lowered its 2015 revenue outlook due to higher than anticipated churn, predominantly from a small number of larger data center services customers.

Buffalo Wild Wings Inc. (BWLD) was down 10 percent to $165.50 after reporting first quarter results that missed Street view. At the same time, the company said that its net earnings growth goal for 2015 remains 18 percent.

Akamai Technologies, Inc. (AKAM) declined 7 percent to $70.72. The company's firt quarter earnings were higher than in the year-ago quarter, while its adjusted earnings per share were in-line with Street view. Revenue improved 16 percent and just managed to come marginally ahead of expectation.

United States Steel Corp. (X) fell 6 percent to $25.00. The company slipped to a loss in its first quarter, stating that its results reflect extremely challenging market conditions, including the negative impact of the tremendously high levels of imports. Revenues for the quarter declined from last year and also missed the consensus estimate. The company said it is currently operating in the face of extremely difficult conditions, particularly in North America.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.
Editors Pick
Elon Musk's brain implant firm Neuralink said it has received approval from the U.S. Food and Drug Administration to conduct first-in-human clinical trials. In a tweet, Neuralink said, "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study! T.W. Garner Food Co. is recalling 50,688 bottles of 12 oz. Texas Pete Buffalo Wing Sauce citing undeclared soy, the U.S. Food and Drug Administration said. The agency noted that some of the bottles may contain Texas Pete Extra Mild Wing Sauce which contains soy. The recall involves Texas Pete Buffalo Wing Sauce with best used by 120623T 065239 UPC 0 75500 10011 6. The U.S. Food and Drug Administration approved Pfizer Inc's COVID-19 oral antiviral pill Paxlovid for the treatment of mild-to-moderate COVID-19 in adults. Paxlovid is the first oral treatment, and the fourth drug, approved by the agency to treat COVID-19 in adults. Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) has been approved to treat adults who are at high...
Follow RTT